Skip to main content
. 2020 Dec 20;28(3):454–463. doi: 10.1111/jvh.13456

TABLE 3.

Pooled results from the treatment safety of included studies

Side effects

n (%)

Intervention n (%) Discontinuation n (%)

Adverse events

n (%)

Reduction of immunosuppressive medication (21 studies, 174 patients) 3 (2) 3 (2) NA 2 (1)
Ribavirin (34 studies, 395 patients) 122 (31) 142 (36) 8 (2) 4 (1)
Pegylated interferon‐α (8 studies, 13 patients) 5 (38) 5 (38) 2 (15) 2 (15)